JP2022551105A5 - - Google Patents

Info

Publication number
JP2022551105A5
JP2022551105A5 JP2022520638A JP2022520638A JP2022551105A5 JP 2022551105 A5 JP2022551105 A5 JP 2022551105A5 JP 2022520638 A JP2022520638 A JP 2022520638A JP 2022520638 A JP2022520638 A JP 2022520638A JP 2022551105 A5 JP2022551105 A5 JP 2022551105A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
eosinophilic
therapeutically effective
effective dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022520638A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022551105A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/054221 external-priority patent/WO2021067917A1/en
Publication of JP2022551105A publication Critical patent/JP2022551105A/ja
Publication of JP2022551105A5 publication Critical patent/JP2022551105A5/ja
Priority to JP2025135336A priority Critical patent/JP2025169361A/ja
Pending legal-status Critical Current

Links

JP2022520638A 2019-10-04 2020-10-05 アバプリチニブでの好酸球性障害の治療 Pending JP2022551105A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025135336A JP2025169361A (ja) 2019-10-04 2025-08-15 アバプリチニブでの好酸球性障害の治療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962910931P 2019-10-04 2019-10-04
US62/910,931 2019-10-04
PCT/US2020/054221 WO2021067917A1 (en) 2019-10-04 2020-10-05 Treatment of eosinophilic disorders with avapritinib

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025135336A Division JP2025169361A (ja) 2019-10-04 2025-08-15 アバプリチニブでの好酸球性障害の治療

Publications (2)

Publication Number Publication Date
JP2022551105A JP2022551105A (ja) 2022-12-07
JP2022551105A5 true JP2022551105A5 (cg-RX-API-DMAC7.html) 2023-10-13

Family

ID=73030210

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022520638A Pending JP2022551105A (ja) 2019-10-04 2020-10-05 アバプリチニブでの好酸球性障害の治療
JP2025135336A Pending JP2025169361A (ja) 2019-10-04 2025-08-15 アバプリチニブでの好酸球性障害の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025135336A Pending JP2025169361A (ja) 2019-10-04 2025-08-15 アバプリチニブでの好酸球性障害の治療

Country Status (6)

Country Link
US (1) US20240075041A1 (cg-RX-API-DMAC7.html)
EP (1) EP4041244B1 (cg-RX-API-DMAC7.html)
JP (2) JP2022551105A (cg-RX-API-DMAC7.html)
CN (1) CN114746096A (cg-RX-API-DMAC7.html)
TW (1) TW202126306A (cg-RX-API-DMAC7.html)
WO (1) WO2021067917A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX365614B (es) 2013-10-17 2019-06-07 Blueprint Medicines Corp Composiciones utiles para tratar trastornos relacionados con kit.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2593319T3 (es) * 2005-05-02 2016-12-07 Novartis Ag Derivados de pirimidilaminobenzamida para síndrome hipereosinofílico
JP2009515978A (ja) * 2005-11-14 2009-04-16 バイエル ヘルスケア エルエルシー Kit阻害剤に対する獲得耐性を伴う癌の治療
ES2429107T3 (es) * 2007-01-19 2013-11-13 Bayer Healthcare Llc Tratamiento de cánceres con una resistencia adquirida a los agentes inhibidores de KIT
ES2573831T3 (es) * 2011-07-27 2016-06-10 Ab Science Derivados de oxazol y tiazol como inhibidores selectivos de la proteína quinasa (C-kit)
EP2768480A1 (en) * 2011-10-21 2014-08-27 Rigel Pharmaceuticals, Inc. Method and device for administering xinafoate salt of n4-(2,2-difluoro-4h-benzo [1,4]oxazin-3-one) -6-yl]-5-fluoro-n2- [3- (methylaminocarbonylmethyleneoxy) phenyl]2,4-pyrimidinediamine
KR101652229B1 (ko) * 2012-06-07 2016-08-30 데시페라 파마슈티칼스, 엘엘씨. 증식성 질환의 치료를 위한 키나제 저해제로서 유용한 다이하이드로나프타이리딘 및 관련 화합물
MX365614B (es) * 2013-10-17 2019-06-07 Blueprint Medicines Corp Composiciones utiles para tratar trastornos relacionados con kit.
CN109970745B (zh) * 2018-04-16 2020-12-08 深圳市塔吉瑞生物医药有限公司 取代的吡咯并三嗪类化合物及其药物组合物及其用途

Similar Documents

Publication Publication Date Title
JP2023002662A5 (cg-RX-API-DMAC7.html)
JP2024133474A5 (cg-RX-API-DMAC7.html)
JP2022009090A5 (cg-RX-API-DMAC7.html)
JP2006523216A5 (cg-RX-API-DMAC7.html)
JP2021098728A5 (cg-RX-API-DMAC7.html)
JP2005537268A5 (cg-RX-API-DMAC7.html)
JP2022191257A5 (cg-RX-API-DMAC7.html)
JP2022545835A5 (cg-RX-API-DMAC7.html)
JP2007515469A5 (cg-RX-API-DMAC7.html)
JP2005515966A5 (cg-RX-API-DMAC7.html)
JP2026035701A5 (cg-RX-API-DMAC7.html)
JP2016517434A5 (cg-RX-API-DMAC7.html)
JP2012521435A5 (cg-RX-API-DMAC7.html)
JP2023523569A5 (cg-RX-API-DMAC7.html)
JP2023548055A5 (cg-RX-API-DMAC7.html)
JP2022533368A5 (cg-RX-API-DMAC7.html)
JP2009530295A5 (cg-RX-API-DMAC7.html)
JP2022116304A (ja) 血液がんの治療のためのPPARγアゴニスト
JP2006516571A5 (cg-RX-API-DMAC7.html)
EP4494701A3 (en) New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases
JP2021534160A5 (cg-RX-API-DMAC7.html)
JP2024502446A5 (cg-RX-API-DMAC7.html)
RU2007107915A (ru) Лекарственные средства для лечения хронического респираторного заболевания
JP2005512946A5 (cg-RX-API-DMAC7.html)
JP2019524888A5 (cg-RX-API-DMAC7.html)